Oral Delivery of Protein Drugs Bioencapsulated in Plant Cells

Molecular Therapy

Volumn 24, Issue 8, 2016, Pages 1342-1350

  Kwon, Kwang Chul ^a   Daniell, Henry ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN DRUG; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; BIOLOGICAL PRODUCT; PROTEIN;

AGROBACTERIUM TUMEFACIENS; ALZHEIMER DISEASE; BACTEROIDES FRAGILIS; BLOOD BRAIN BARRIER; BLOOD RETINA BARRIER; CELL WALL; CHLOROPLAST; DIABETES MELLITUS; DRUG DELIVERY SYSTEM; GAUCHER DISEASE; GOOD MANUFACTURING PRACTICE; HUMAN; INTESTINE; NANOENCAPSULATION; NONHUMAN; PLANT CELL; PULMONARY HYPERTENSION; REVIEW; TRANSMUCOSAL DRUG DELIVERY SYSTEM; ANIMAL; CELL NUCLEUS; CYTOLOGY; DRUG EFFECTS; IMMUNE SYSTEM; IMMUNOLOGY; METABOLISM; MUCOSA; ORAL DRUG ADMINISTRATION; PROTEIN SYNTHESIS; RETINA;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL PRODUCTS; BLOOD-BRAIN BARRIER; CELL NUCLEUS; CHLOROPLASTS; DRUG DELIVERY SYSTEMS; HUMANS; IMMUNE SYSTEM; MUCOUS MEMBRANE; PLANT CELLS; PROTEIN BIOSYNTHESIS; PROTEINS; RETINA;

EID: 84977119389     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2016.115     Document Type: Review

References (127)

1. Craik, DJ, Fairlie, DP, Liras, S and Price, D (2013). The future of peptide-based drugs. Chem Biol Drug Des 81: 136-147.
2. Walsh, G (2014). Biopharmaceutical benchmarks. Nat Biotechnol 32: 992-1000.
3. Daniell, H, Singh, ND, Mason, H and Streatfield, SJ (2009). Plant-made vaccine antigens and biopharmaceuticals. Trends Plant Sci 14: 669-679.
4. Kwon, KC, Verma, D, Singh, ND, Herzog, R and Daniell, H (2013). Oral delivery of human biopharmaceuticals, autoantigens and vaccine antigens bioencapsulated in plant cells. Adv Drug Deliv Rev 65: 782-799.
5. Ma, JK, Drake, PM and Christou, P (2003). The production of recombinant pharmaceutical proteins in plants. Nat Rev Genet 4: 794-805.
6. Sp, A and Karner, S (2008). Plant Molecular Farming: Opportunities and Challenges. AJ Stein (Ed.) European Commission: The Institute for Prospective Technological Studies, Seville. http://ftp.jrc.es/EURdoc/
7. Renukuntla, J, Vadlapudi, AD, Patel, A, Boddu, SH and Mitra, AK (2013). Approaches for enhancing oral bioavailability of peptides and proteins. Int J Pharm 447: 75-93.
8. Diago, M, Crespo, J, Olveira, A, Pez, R, Bcena, R, Schez-Tapias, JM et al. (2007). Clinical trial: pharmacodynamics and pharmacokinetics of re-treatment with fixed-dose induction of peginterferon alpha-2a in hepatitis C virus genotype 1 true non-responder patients. Aliment Pharmacol Ther 26: 1131-1138.
9. Kumar, TR, Soppimath, K and Nachaegari, SK (2006). Novel delivery technologies for protein and peptide therapeutics. Curr Pharm Biotechnol 7: 261-276.
10. Baggio, LL, Huang, Q, Brown, TJ and Drucker, DJ (2004). A recombinant human glucagon-like peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis. Diabetes 53: 2492-2500.
11. Subramanian, GM, Fiscella, M, LamousSmith, A, Zeuzem, S and McHutchison, JG (2007). Albinterferon alpha-2b: a genetic fusion protein for the treatment of chronic hepatitis C. Nat Biotechnol 25: 1411-1419.
12. Werle, M and Bernkop-Schnch, A (2006). Strategies to improve plasma half life time of peptide and protein drugs. Amino Acids 30: 351-367.
13. Martens, EC, Lowe, EC, Chiang, H, Pudlo, NA, Wu, M, McNulty, NP et al. (2011). Recognition and degradation of plant cell wall polysaccharides by two human gut symbionts. PLoS Biol 9: e1001221.
14. Flint, HJ, Scott, KP, Duncan, SH, Louis, P and Forano, E (2012). Microbial degradation of complex carbohydrates in the gut. Gut Microbes 3: 289-306.
15. Stoger, E, Fischer, R, Moloney, M and Ma, JK (2014). Plant molecular pharming for the treatment of chronic and infectious diseases. Annu Rev Plant Biol 65: 743-768.
16. Gao, J and Yin, L (2014). Drug development for controlling Ebola epidemic-A race against time. Drug Discov Ther 8: 229-231.
17. Shaaltiel, Y, Bartfeld, D, Hashmueli, S, Baum, G, Brill-Almon, E, Galili, G et al. (2007). Production of glucocerebrosidase with terminal mannose glycans for enzyme replacement therapy of Gaucher's disease using a plant cell system. Plant Biotechnol J 5: 579-590.
18. Su, J, Zhu, L, Sherman, A, Wang, X, Lin, S, Kamesh, A et al. (2015). Low cost industrial production of coagulation factor IX bioencapsulated in lettuce cells for oral tolerance induction in hemophilia B. Biomaterials 70: 84-93.
19. Sanz-Barrio, R, Ferndez-San Mill, A, Carballeda, J, Corral-Martez, P, Segu Simarro, JM and Farran, I (2012). Chaperone-like properties of tobacco plastid thioredoxins f and m. J Exp Bot 63: 365-379.
20. Barta, A, Sommergruber, K, Thompson, D, Hartmuth, K, Matzke, MA and Matzke, AJ (1986). The expression of a nopaline synthase-human growth hormone chimaeric gene in transformed tobacco and sunflower callus tissue. Plant Mol Biol 6: 347-357.
21. Daniell, H, Lee, SB, Panchal, T and Wiebe, PO (2001). Expression of the native cholera toxin B subunit gene and assembly as functional oligomers in transgenic tobacco chloroplasts. J Mol Biol 311: 1001-1009.
22. Ferndez-San Mill, A, Mingo-Castel, A, Miller, M and Daniell, H (2003). A chloroplast transgenic approach to hyper-express and purify Human Serum Albumin, a protein highly susceptible to proteolytic degradation. Plant Biotechnol J 1: 71-79.
23. Staub, JM, Garcia, B, Graves, J, Hajdukiewicz, PT, Hunter, P, Nehra, N et al. (2000). High-yield production of a human therapeutic protein in tobacco chloroplasts. Nat Biotechnol 18: 333-338.
24. Basaran, P and Rodruez-Cerezo, E (2008). Plant molecular farming: opportunities and challenges. Crit Rev Biotechnol 28: 153-172.
25. Xu, J, Dolan, MC, Medrano, G, Cramer, CL and Weathers, PJ (2012). Green factory: plants as bioproduction platforms for recombinant proteins. Biotechnol Adv 30: 1171-1184.
26. Fahad, S, Khan, FA, Pandupuspitasari, NS, Ahmed, MM, Liao, YC, Waheed, MT et al. (2015). Recent developments in therapeutic protein expression technologies in plants. Biotechnol Lett 37: 265-279.
27. Daniell, H, Khan, MS and Allison, L (2002). Milestones in chloroplast genetic engineering: an environmentally friendly era in biotechnology. Trends Plant Sci 7: 84-91.
28. Chebolu, S and Daniell, H (2009). Chloroplast-derived vaccine antigens and biopharmaceuticals: expression, folding, assembly and functionality. Curr Top Microbiol Immunol 332: 33-54.
29. Jin, S and Daniell, H (2015). The engineered chloroplast genome just got smarter. Trends Plant Sci 20: 622-640.
30. Waheed, MT, Ismail, H, Gottschamel, J, Mirza, B and Lsl, AG (2015). Plastids: The green frontiers for vaccine production. Front Plant Sci 6: 1005.
31. Ruhlman, T, Verma, D, Samson, N and Daniell, H (2010). The role of heterologous chloroplast sequence elements in transgene integration and expression. Plant Physiol 152: 2088-2104.
32. De Cosa, B, Moar, W, Lee, SB, Miller, M and Daniell, H (2001). Overexpression of the Bt cry2Aa2 operon in chloroplasts leads to formation of insecticidal crystals. Nat Biotechnol 19: 71-74.
33. Quesada-Vargas, T, Ruiz, ON and Daniell, H (2005). Characterization of heterologous multigene operons in transgenic chloroplasts: transcription, processing, and translation. Plant Physiol 138: 1746-1762.
34. Kumar, S, Hahn, FM, Baidoo, E, Kahlon, TS, Wood, DF, McMahan, CM et al. (2012). Remodeling the isoprenoid pathway in tobacco by expressing the cytoplasmic mevalonate pathway in chloroplasts. Metab Eng 14: 19-28.
35. Saxena, B, Subramaniyan, M, Malhotra, K, Bhavesh, NS, Potlakayala, SD and Kumar, S (2014). Metabolic engineering of chloroplasts for artemisinic acid biosynthesis and impact on plant growth. J Biosci 39: 33-41.
36. Lee, SB, Kwon, HB, Kwon, SJ, Park, SC, Jeong, MJ, Han, SE et al. (2003). Accumulation of trehalose within transgenic chloroplasts confers drought tolerance. Mol Breeding 11: 1-13.
37. Daniell, H (2007). Transgene containment by maternal inheritance: effective or elusive Proc Natl Acad Sci USA 104: 6879-6880.
38. Wilson, JP (1967). Surface area of the small intestine in man. Gut 8: 618-621.
39. Limaye, A, Koya, V, Samsam, M and Daniell, H (2006). Receptor-mediated oral delivery of a bioencapsulated green fluorescent protein expressed in transgenic chloroplasts into the mouse circulatory system. FASEB J 20: 959-961.
40. Xiao, Y, Kwon, KC, Hoffman, BE, Kamesh, A, Jones, NT, Herzog, RW et al. (2016). Low cost delivery of proteins bioencapsulated in plant cells to human non-immune or immune modulatory cells. Biomaterials 80: 68-79.
41. Flint, HJ, Bayer, EA, Rincon, MT, Lamed, R and White, BA (2008). Polysaccharide utilization by gut bacteria: potential for new insights from genomic analysis. Nat Rev Microbiol 6: 121-131.
42. Koropatkin, NM, Cameron, EA and Martens, EC (2012). How glycan metabolism shapes the human gut microbiota. Nat Rev Microbiol 10: 323-335.
43. Wernick, NL, Chinnapen, DJ, Cho, JA and Lencer, WI (2010). Cholera toxin: an intracellular journey into the cytosol by way of the endoplasmic reticulum. Toxins (Basel) 2: 310-325.
44. Saslowsky, DE, te Welscher, YM, Chinnapen, DJ, Wagner, JS, Wan, J, Kern, E et al. (2013). Ganglioside GM1-mediated transcytosis of cholera toxin bypasses the retrograde pathway and depends on the structure of the ceramide domain. J Biol Chem 288: 25804-25809.
45. Noguchi, H, Matsushita, M, Matsumoto, S, Lu, YF, Matsui, H and Bonner-Weir, S (2005). Mechanism of PDX-1 protein transduction. Biochem Biophys Res Commun 332: 68-74.
46. Durzyska, J, Przysiecka, Nawrot, R, Barylski, J, Nowicki, G, Warowicka, A et al. (2015). Viral and other cell-penetrating peptides as vectors of therapeutic agents in medicine. J Pharmacol Exp Ther 354: 32-42.
47. Ohno, H (2016). Intestinal M cells. J Biochem 159: 151-160.
48. Wang, X, Sherman, A, Liao, G, Leong, KW, Daniell, H, Terhorst, C et al. (2013). Mechanism of oral tolerance induction to therapeutic proteins. Adv Drug Deliv Rev 65: 759-773.
49. Kwon, KC, Nityanandam, R, New, JS and Daniell, H (2013). Oral delivery of bioencapsulated exendin-4 expressed in chloroplasts lowers blood glucose level in mice and stimulates insulin secretion in beta-TC6 cells. Plant Biotechnol J 11: 77-86.
50. Shenoy, V, Kwon, KC, Rathinasabapathy, A, Lin, S, Jin, G, Song, C et al. (2014). Oral delivery of Angiotensin-converting enzyme 2 and Angiotensin-(1-7) bioencapsulated in plant cells attenuates pulmonary hypertension. Hypertension 64: 1248-1259.
51. Thomas, G (2002). Furin at the cutting edge: from protein traffic to embryogenesis and disease. Nat Rev Mol Cell Biol 3: 753-766.
52. Vighi, G, Marcucci, F, Sensi, L, Di Cara, G and Frati, F (2008). Allergy and the gastrointestinal system. Clin Exp Immunol 153 Suppl 1: 3-6.
53. Chan, HT and Daniell, H (2015). Plant-made oral vaccines against human infectious diseases-Are we there yet Plant Biotechnol J 13: 1056-1070.
54. Chan, HT, Xiao, Y, Weldon, WC, Oberste, SM, Chumakov, K and Daniell, H (2016). Cold chain and virus free chloroplast-made booster vaccine to confer immunity against different polio virus serotypes. Plant Biotechnol J doi: 10.1111/pbi.12575.
55. Sun, JB, Holmgren, J and Czerkinsky, C (1994). Cholera toxin B subunit: an efficient transmucosal carrier-delivery system for induction of peripheral immunological tolerance. Proc Natl Acad Sci USA 91: 10795-10799.
56. Odumosu, O, Nicholas, D, Yano, H and Langridge, W (2010). AB toxins: a paradigm switch from deadly to desirable. Toxins (Basel) 2: 1612-1645.
57. Schez, J and Holmgren, J (2008). Cholera toxin structure, gene regulation and pathophysiological and immunological aspects. Cell Mol Life Sci 65: 1347-1360.
58. Holmgren, J, Lnroth, I, Msson, J and Svennerholm, L (1975). Interaction of cholera toxin and membrane GM1 ganglioside of small intestine. Proc Natl Acad Sci USA 72: 2520-2524.
59. Fishman, PH, Bradley, RM, Hom, BE and Moss, J (1983). Uptake and metabolism of exogenous gangliosides by cultured cells: effect of choleragen on the turnover of GM1. J Lipid Res 24: 1002-1011.
60. Ruhlman, T, Ahangari, R, Devine, A, Samsam, M and Daniell, H (2007). Expression of cholera toxin B-proinsulin fusion protein in lettuce and tobacco chloroplasts-oral administration protects against development of insulitis in non-obese diabetic mice. Plant Biotechnol J 5: 495-510.
61. Boyhan, D and Daniell, H (2011). Low-cost production of proinsulin in tobacco and lettuce chloroplasts for injectable or oral delivery of functional insulin and C-peptide. Plant Biotechnol J 9: 585-598.
62. Kohli, N, Westerveld, DR, Ayache, AC, Verma, A, Shil, P, Prasad, T et al. (2014). Oral delivery of bioencapsulated proteins across blood-brain and blood-retinal barriers. Mol Ther 22: 535-546.
63. Shil, PK, Kwon, KC, Zhu, P, Verma, A, Daniell, H and Li, Q (2014). Oral delivery of ACE2/Ang-(1-7) bioencapsulated in plant cells protects against experimental uveitis and autoimmune uveoretinitis. Mol Ther 22: 2069-2082.
64. Sherman, A, Su, J, Lin, S, Wang, X, Herzog, RW and Daniell, H (2014). Suppression of inhibitor formation against FVIII in a murine model of hemophilia A by oral delivery of antigens bioencapsulated in plant cells. Blood 124: 1659-1668.
65. Su, J, Sherman, A, Doerfler, PA, Byrne, BJ, Herzog, RW and Daniell, H (2015). Oral delivery of Acid Alpha Glucosidase epitopes expressed in plant chloroplasts suppresses antibody formation in treatment of Pompe mice. Plant Biotechnol J 13: 1023-1032.
66. Verma, D, Moghimi, B, LoDuca, PA, Singh, HD, Hoffman, BE, Herzog, RW et al. (2010). Oral delivery of bioencapsulated coagulation factor IX prevents inhibitor formation and fatal anaphylaxis in hemophilia B mice. Proc Natl Acad Sci USA 107: 7101-7106.
67. Wang, X, Su, J, Sherman, A, Rogers, GL, Liao, G, Hoffman, BE et al. (2015). Plantbased oral tolerance to hemophilia therapy employs a complex immune regulatory response including LAP+CD4+ T cells. Blood 125: 2418-2427.
68. Davoodi-Semiromi, A, Schreiber, M, Nalapalli, S, Verma, D, Singh, ND, Banks, RK et al. (2010). Chloroplast-derived vaccine antigens confer dual immunity against cholera and malaria by oral or injectable delivery. Plant Biotechnol J 8: 223-242.
69. Yu, J and Langridge, WH (2001). A plant-based multicomponent vaccine protects mice from enteric diseases. Nat Biotechnol 19: 548-552.
70. Miyata, T, Oshiro, S, Harakuni, T, Taira, T, Matsuzaki, G and Arakawa, T (2012). Physicochemically stable cholera toxin B subunit pentamer created by peripheral molecular constraints imposed by de novo-introduced intersubunit disulfide crosslinks. Vaccine 30: 4225-4232.
71. Zahid, M and Robbins, PD (2012). Protein transduction domains: applications for molecular medicine. Curr Gene Ther 12: 374-380.
72. Curiel, TJ, Morris, C, Brumlik, M, Landry, SJ, Finstad, K, Nelson, A et al. (2004). Peptides identified through phage display direct immunogenic antigen to dendritic cells. J Immunol 172: 7425-7431.
73. Calder, PC, Dimitriadis, G and Newsholme, P (2007). Glucose metabolism in lymphoid and inflammatory cells and tissues. Curr Opin Clin Nutr Metab Care 10: 531-540.
74. Hadjiconstantinou, M and Neff, NH (1998). GM1 ganglioside: in vivo and in vitro trophic actions on central neurotransmitter systems. J Neurochem 70: 1335-1345.
75. Mer, I, Roberts, TC, Wood, MJ and El Andaloussi, S (2014). From gut to brain: bioencapsulated therapeutic protein reduces amyloid load upon oral delivery. Mol Ther 22: 485-486.
76. Fu, HJ, Liu, B, Frost, JL and Lemere, CA (2010). Amyloid-beta immunotherapy for Alzheimer's disease. CNS Neurol Disord Drug Targets 9: 197-206.
77. Salloway, S, Sperling, R, Fox, NC, Blennow, K, Klunk, W, Raskind, M et al.; Bapineuzumab 301 and 302 Clinical Trial Investigators (2014). Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med 370: 322-333.
78. Gabathuler, R (2010). Approaches to transport therapeutic drugs across the bloodbrain barrier to treat brain diseases. Neurobiol Dis 37: 48-57.
79. Stojanov, K, Georgieva, JV, Brinkhuis, RP, van Hest, JC, Rutjes, FP, Dierckx, RA et al. (2012). In vivo biodistribution of prion-and GM1-targeted polymersomes following intravenous administration in mice. Mol Pharm 9: 1620-1627.
80. Bull, ND, Guidi, A, Goedert, M, Martin, KR and Spillantini, MG (2012). Reduced axonal transport and increased excitotoxic retinal ganglion cell degeneration in mice transgenic for human mutant P301S tau. PLoS One 7: e34724.
81. Thrimawithana, TR, Young, S, Bunt, CR, Green, C and Alany, RG (2011). Drug delivery to the posterior segment of the eye. Drug Discov Today 16: 270-277.
82. Bucolo, C, Drago, F and Salomone, S (2012). Ocular drug delivery: a clue from nanotechnology. Front Pharmacol 3: 188.
83. Zimran, A and Elstein, D (2014). Management of Gaucher disease: enzyme replacement therapy. Pediatr Endocrinol Rev 12 Suppl 1: 82-87.
84. Qiu, X, Wong, G, Audet, J, Bello, A, Fernando, L, Alimonti, JB et al. (2014). Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature 514: 47-53.
85. Grabowski, GA (2008). Phenotype, diagnosis, and treatment of Gaucher's disease. Lancet 372: 1263-1271.
86. In brief: Taliglucerase (Elelyso) for Gaucher disease (2012). Med Lett Drugs Ther 54:56.
87. Shaaltiel, Y, Gingis-Velitski, S, Tzaban, S, Fiks, N, Tekoah, Y and Aviezer, D (2015). Plant-based oral delivery of-glucocerebrosidase as an enzyme replacement therapy for Gaucher's disease. Plant Biotechnol J 13: 1033-1040.
88. Whiting, DR, Guariguata, L, Weil, C and Shaw, J (2011). IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract 94: 311-321.
89. Patel, YR (2006). Drug delivery in diabetes: making effective treatment tolerable. ONdrugDelivery. http://www.ondrugdelivery.com/publications/diabetes.pdf.
90. Nitesh, SC, Sanjeev, C, Vandana, H, Alka, A and Vijender, S (2010). Recent advances in insulin delivery systems: An update. World Appl Sci J 11:1552-1556.
91. Zijlstra, E, Heinemann, L and Plum-Mschel, L (2014). Oral insulin reloaded: a structured approach. J Diabetes Sci Technol 8: 458-465.
92. Wahren, J, Ekberg, K and Jnvall, H (2007). C-peptide is a bioactive peptide. Diabetologia 50: 503-509.
93. Wahren, J and Larsson, C (2015). C-peptide: new findings and therapeutic possibilities. Diabetes Res Clin Pract 107: 309-319.
94. Kim, W and Egan, JM (2008). The role of incretins in glucose homeostasis and diabetes treatment. Pharmacol Rev 60: 470-512.
95. Choi, J, Diao, H, Feng, ZC, Lau, A, Wang, R, Jevnikar, AM et al. (2014). A fusion protein derived from plants holds promising potential as a new oral therapy for type 2 diabetes. Plant Biotechnol J 12: 425-435.
96. Simonneau, G, Gatzoulis, MA, Adatia, I, Celermajer, D, Denton, C, Ghofrani, A et al. (2013). Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 62(25 Suppl): D34-D41.
97. Montani, D, Gther, S, Dorfmler, P, Perros, F, Girerd, B, Garcia, G et al. (2013). Pulmonary arterial hypertension. Orphanet J Rare Dis 8: 97.
98. Duarte, JD, Hanson, RL and Machado, RF (2013). Pharmacologic treatments for pulmonary hypertension: exploring pharmacogenomics. Future Cardiol 9: 335-349.
99. Gomberg-Maitland, M and Olschewski, H (2008). Prostacyclin therapies for the treatment of pulmonary arterial hypertension. Eur Respir J 31: 891-901.
100. Humbert, M, Sitbon, O, Chaouat, A, Bertocchi, M, Habib, G, Gressin, V et al. (2010). Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation 122: 156-163.
101. Phillips, MI and Sumners, C (1998). Angiotensin II in central nervous system physiology. Regul Pept 78: 1-11.
102. Fein, A (2009). ACE inhibitors worsen inflammatory pain. Med Hypotheses 72: 757.
103. Sidorenkov, G and Navis, G (2014). Safety of ACE inhibitor therapies in patients with chronic kidney disease. Expert Opin Drug Saf 13: 1383-1395.
104. Tipnis, SR, Hooper, NM, Hyde, R, Karran, E, Christie, G and Turner, AJ (2000). A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. J Biol Chem 275: 33238-33243.
105. Donoghue, M, Hsieh, F, Baronas, E, Godbout, K, Gosselin, M, Stagliano, N et al. (2000). A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res 87: E1-E9.
106. Clarke, NE and Turner, AJ (2012). Angiotensin-converting enzyme 2: the first decade. Int J Hypertens 2012: 307-315.
107. Kassiri, Z, Zhong, J, Guo, D, Basu, R, Wang, X, Liu, PP et al. (2009). Loss of angiotensin-converting enzyme 2 accelerates maladaptive left ventricular remodeling in response to myocardial infarction. Circ Heart Fail 2: 446-455.
108. Grobe, JL, Mecca, AP, Mao, H and Katovich, MJ (2006). Chronic angiotensin-(1-7) prevents cardiac fibrosis in DOCA-salt model of hypertension. Am J PhysiolHeart Circ Physiol 290: H2417-H2423.
109. Qi, Y, Shenoy, V and Wong, F, Li, H, Afzal, A and Mocco, J et al. (2011). Lentiviral mediated overexpression of Angiotensin-(1-7) attenuated ischemia induced cardiac pathophysiology. Exp Physiol 96: 863-874.
110. Haschke, M, Schuster, M, Poglitsch, M, Loibner, H, Salzberg, M, Bruggisser, M et al. (2013). Pharmacokinetics and pharmacodynamics of recombinant human angiotensinconverting enzyme 2 in healthy human subjects. Clin Pharmacokinet 52: 783-792.
111. Wakasa, Y, Zhao, H, Hirose, S, Yamauchi, D, Yamada, Y, Yang, L et al. (2011). Antihypertensive activity of transgenic rice seed containing an 18-repeat novokinin peptide localized in the nucleolus of endosperm cells. Plant Biotechnol J 9: 729-735.
112. Wakasa, Y, Tamakoshi, C, Ohno, T, Hirose, S, Goto, T, Nagaoka, S et al. (2011). The hypocholesterolemic activity of transgenic rice seed accumulating lactostatin, a bioactive peptide derived from bovine milk-lactoglobulin. J Agric Food Chem 59: 3845-3850.
113. Baker, CW, Jiang, Y and Stone, T (2016). Recent advancements in diabetic retinopathy treatment from the Diabetic Retinopathy Clinical Research Network. Curr Opin Ophthalmol 27: 210-216.
114. Duthey, B (2013). Background paper 6.11: Alzheimer disease and other dementias. A Public Health Approach to Innovation, Update on 2004 Background Paper. pp. 1-74.
115. Hansen, RA, Gartlehner, G, Webb, AP, Morgan, LC, Moore, CG and Jonas, DE (2008). Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis. Clin Interv Aging 3: 211-225.
116. Reisberg, B, Doody, R, Stfler, A, Schmitt, F, Ferris, S and Mius, HJ; Memantine Study Group (2003). Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 348: 1333-1341.
117. Check, E (2002). Nerve inflammation halts trial for Alzheimer's drug. Nature 415: 462.
118. Doody, RS, Thomas, RG, Farlow, M, Iwatsubo, T, Vellas, B, Joffe, S et al.; Alzheimer's Disease Cooperative Study Steering Committee; Solanezumab Study Group. (2014). Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N Engl J Med 370: 311-321.
119. Liao, MC, Hoos, MD, Aucoin, D, Ahmed, M, Davis, J, Smith, SO et al. (2010). N-terminal domain of myelin basic protein inhibits amyloid beta-protein fibril assembly. J Biol Chem 285: 35590-35598.
120. Lee, AG and Martin, CO (2004). Neuro-ophthalmic findings in the visual variant of Alzheimer's disease. Ophthalmol111: 376-80; discussion 380.
121. Daniell, H, Chan, HT and Pasoreck, EK (2016). Vaccination through chloroplast genetics: affordable protein drugs for the prevention and treatment of inherited or infectious diseases. Annu Rev Genet 50 (in press).
122. Daniell, H, Lin, CS, Yu, M and Chang, WC (2016). Chloroplast genomes: diversity, evolution and applications in genetic engineering. Genome Biol DOI 10.1186/s13059-016-1004-2.
123. Kim, JW and You, J (2013). Protein target quantification decision tree. Int J Proteomics 2013: 1-8.
124. Gallien, S, Duriez, E, Crone, C, Kellmann, M, Moehring, T and Domon, B (2012). Targeted proteomic quantification on quadrupole-orbitrap mass spectrometer. Mol Cell Proteomics 11: 1709-1723.
125. Kwon, KC, Chan, HT, Le, IR, Williams-Carrier, R, Barkan, A and Daniell, H (2016). Use of genomic, proteomic and ribosome profiling tools for comparative analysis of native and codon optimized human or viral genes enhances understanding of transgene expression in chloroplasts. Plant Physiol (in press).
126. Berntorp, E and Shapiro, AD (2012). Modern haemophilia care. Lancet 379: 1447-1456.
127. Leissinger, CA (2004). Prevention of bleeds in hemophilia patients with inhibitors: emerging data and clinical direction. Am J Hematol 77: 187-193.